**This commentary refers to '2018 ESC guidelines for the diagnosis of syncope', by M. Brignole *et al.*, pages 1883--1948.**

Orthostatic hypotension (OH) can cause serious and potentially disabling symptoms and is associated with an increased risk of morbidity and mortality, particularly because of hazards from falls.[@ehy779-B1] The 2018 European Society of Cardiology (ESC) guidelines for the diagnosis and management of syncope provide clinicians with important updates regarding the recognition and treatment of OH.[@ehy779-B2] These guidelines outline the utility of droxidopa as a treatment for symptomatic OH due to autonomic failure \[neurogenic OH (nOH)\] based on data from short-term Phase 3 clinical trials.

Recent data from a 12-month open-label extension study of droxidopa in patients with symptomatic nOH suggest the durability of benefits with long-term droxidopa treatment, including sustained increases in standing blood pressure and, more importantly, sustained improvements in patient-reported assessments of nOH symptom severity, in symptom effect on daily activities, and in the Clinical Global Impressions scale.[@ehy779-B3]

The long-term efficacy of droxidopa treatment was also evaluated in a 6-month prospective study of patients with nOH initiating droxidopa treatment. This patient cohort reported improvements in falls, functionality, depressive symptoms, and health-related quality of life (HRQoL) with droxidopa treatment.[@ehy779-B4] Specifically, fewer patients reported a fall in the 1 month after initiating droxidopa treatment vs. the month before treatment (43% vs. 53%; *P *=* *0.004); this reduced rate of falls was maintained at 6 months (40%; *P *=* *0.034 vs. baseline). Other patient-reported assessments also showed significant improvements, including better functionality (Sheehan Disability Scale global scores, *P *≤* *0.001), fewer depressive symptoms (Patient Health Questionnaire-9 scores, *P *\<* *0.01), and improved HRQoL (Short Form-8 scores, *P ≤ *0.01).

Taken together, the results of these studies suggest that long-term treatment with droxidopa provides sustained benefits to patients with nOH, although there are limitations due to the lack of parallel control groups and the self-reported nature of the data. As noted in the ESC guidelines,[@ehy779-B2] further research into treatment options for OH and the clinical effects of droxidopa is warranted to better guide effective management of patients with this challenging clinical condition.
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